Takara Bio Inc.

Company Overview

Taraka Bio Inc. is a Japan, based life science company. It has facilities all over the globe, including U.S., Sweden, France, Middle East and Africa. They have products for a wide range of activities, including immune profiling, genetic screening, CAR-T therapy, cell and gene therapy, infectious disease research, vaccine development, drug discovery, antibiotic-resistance screening and cancer research.

It has three brand names: Clontech, Takara and Cellartis. Clontech was acquired by Taraka Bio, in the year 2017. It acquired cellatris in the year 2014, expanding its product portfolio. Each brand originated from a separate company with its history and areas of expertise and has since been consolidated under the umbrella of the Takara Bio Group, creating new synergies.

TBU.S.A’s Cellartis brand enables researchers to direct the differentiation of their own iPSC lines. The Cellartis brand has over 15 years of experience providing services and products for research applications involving stem cells. The brand originates from a firm of the same name (now Takara Bio Europe AB), formed by researchers from the University of Gothenburg.

Previously, a primary focus of the Cellartis brand involved developing and distributing stem cell lines, including human embryonic stem cells (hESCs) and hiPSCs, for custom or general applications. More recently, the scope of the brand expanded to include products such as culture systems, media and reagents, which make the expertise and innovative technologies behind the brand more easily accessible to life sciences researchers. A significant milestone for the brand involved the commercialization and development of the Cellartis DEF-CS Culture System, a revolutionary approach to culturing stem cells that offers significant advantages relative to other methods.

The Cellartis iPSC to Hepatocyte Differentiation System is a complete solution for differentiating disease- or patient-specific iPSCs into hepatocytes; it combines a standardized protocol with optimized media, supplements and coating reagents. Cellartis iPS-derived beta cells express mature beta cell markers, including insulin and demonstrate glucose-stimulated insulin secretion after cryopreservation, showing their suitability for in vitro assays.

Financial Highlights (FY 2024)

Company's Business Segments

• Reagents : Research Reagents, Academic, Corporate, Basic research, Advance Research, Life sciences, Biologic development, Applied Research.
• Instruments : Scientific instruments, Academic, Corporate, Clinical laboratories, Medical Institutions, Pathogens, Advance research.
• CDMO : Contract services related to Regenerative medicine products, manufacturing and development of viral, plasid vectors, Gene cells, Quality testing, Safety testing. Biologics development, bio ventures, other research.
• Gene Therapy : Takara Bio aims to maximize the value of its propriertary platform technology for biologics development and purse practical applications for Gene Therapy.